Revolution Medicines’ daraxonrasib drew market attention after data from its Phase 3 RASolute 302 trial in metastatic pancreatic ductal adenocarcinoma. The available reporting described a median overall survival of 13.2 months in the intent-to-treat population versus 6.7 months for standard-of-care chemotherapy, with a hazard ratio of 0.40. Investors reacted strongly to the announcement, with the stock rising sharply following the data release. Jefferies’ analysis framed the readout as exceeding base-case expectations tied to survival duration and effect size versus chemotherapy. The next steps are global regulatory submissions, and the broader signal for KRAS-targeting agents could shape how competitors design subsequent programs in RAS-addicted cancers.